Personalized Mounjaro Protocols in Barcelona: Tirzepatide with Comprehensive Medical Monitoring

Mounjaro: Potency and Medical Responsibility

Pharmacological treatment for excess weight has changed radically in recent years. The emergence of GLP-1 receptor agonists — and more recently dual GIP/GLP-1 agonists like tirzepatide (Mounjaro) — has transformed how medicine approaches obesity and overweight with comorbidities.

Mounjaro (tirzepatide) is one of the most potent drugs currently available for weight management. Clinical trials (SURPASS) show average weight losses of 15-20% of body weight in some groups, figures that surpass those of semaglutide in direct comparisons (SURMOUNT-5).

This potency, however, comes with equally high medical responsibility. Mounjaro is a prescription medication. Its use requires medical evaluation, correct indication, appropriate dose titration, and strict clinical monitoring. At Santé Clínica Estética, we integrate tirzepatide into a complete medical program — we do not administer it as a direct-sale product.

What is Tirzepatide and How Does It Work?

Tirzepatide is a dual agonist of GIP (gastric inhibitory polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. It acts simultaneously on both hormonal systems involved in appetite regulation and metabolism:

GLP-1 Pathway:

• Increases glucose-dependent insulin secretion
• Inhibits glucagon secretion
• Slows gastric emptying (increased feeling of fullness)
• Acts on hypothalamic centers for appetite control

GIP Pathway:

• Improves insulin sensitivity
• Modulates body fat distribution
• Enhances the anorexigenic effect of the GLP-1 pathway

Dual activation produces a more potent effect on appetite and metabolism than GLP-1 activation alone. The clinical result: greater reduction in caloric intake, better control of blood glucose levels, and more pronounced weight loss over time.

Indications: Who is Mounjaro Indicated For?

Tirzepatide is approved for:

• Type 2 Diabetes Mellitus with insufficient glycemic control (primary indication)
• Weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity (hypertension, dyslipidemia, diabetes, obstructive sleep apnea syndrome, cardiovascular disease)

The indication for weight management in patients without type 2 diabetes exists under regulatory authorization in some countries (tirzepatide for obesity was approved in the USA under the brand Zepbound in 2023 and is in the process of approval in Europe for this use in other presentations).

At Santé:

• We evaluate the indication in each case
• We only prescribe after a medical evaluation that includes BMI, body composition, blood tests, comorbidities, and medical history
• We do not prescribe to patients without a clear clinical indication
• We do not administer the drug without an active monitoring program

Why a Personalized Protocol Makes a Difference

Many patients can access tirzepatide more or less directly. What is not accessible in all contexts is the comprehensive medical monitoring protocol that maximizes results and minimizes risks.

At Santé, the Mounjaro protocol includes:

Initial Assessment

• Complete blood work: glycemia, HbA1c, lipid profile, thyroid function, kidney and liver function, sex hormones if applicable
• Body composition: measurement of fat mass, muscle mass, and body water (not just scale weight)
• Medical evaluation: comorbidities, current medication (especially hypoglycemic agents), contraindications
• Establishment of realistic goals: tirzepatide is not a magic solution — results depend on combining it with lifestyle habits

Personalized Dose Titration

Tirzepatide is started at low doses (2.5 mg weekly) and progressively titrated to minimize gastrointestinal side effects (nausea, vomiting, diarrhea). The titration rate is individual: some patients tolerate a 4-week escalation well; others need more time at each step.

The doctor at Santé adjusts titration according to each patient's tolerability and response.

Monthly Monitoring

Each month:

• Review of weight and body composition (not just kilos: maintaining muscle mass is a priority)
• Monitoring of tolerability and dose adjustment if necessary
• Blood test review at 3 months and 6 months
• Nutritional guidance: the diet during tirzepatide treatment has specific characteristics (higher protein to preserve muscle mass, caloric adaptation to lower intake)

Integration with Devices When Indicated

In patients where rapid weight loss can lead to muscle tone loss or skin laxity, the doctor may recommend integration with complementary devices (body INDIBA to maintain muscle tone and improve skin quality during the weight loss process).

The Medical Consultation Has a Cost

It is important to be transparent: the medical consultation for evaluation and initiation of the Mounjaro protocol costs €50. We do not offer free evaluations for drug prescription. This cost reflects the doctor's time, the analytical evaluation, and the medical responsibility of the prescription.

The consultation is not a bureaucratic procedure: it is the moment when it is decided whether Mounjaro is the right option for that patient, at what dose to start, what monitoring is needed, and what goals are realistic.

Side Effects and Management

The most common side effects of tirzepatide are gastrointestinal:

• Nausea: frequent in the first few weeks and when increasing the dose; usually improves over time and with appropriate titration
• Vomiting: less frequent; if intense, the doctor adjusts the dose or slows down titration
• Diarrhea or constipation: frequent; managed with dietary adaptations and, if necessary, symptomatic medication
• Reduced appetite: expected and part of the mechanism of action

In rare cases, pancreatitis, gallstones, or other complications may occur. Regular medical monitoring allows for the detection of warning signs.

Absolute contraindications: personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, active pancreatitis, pregnancy or desire for pregnancy in the short term.

Mounjaro as Part of a Comprehensive Weight Approach

At Santé, we understand weight management as a complex medical process, not a series of injections. Tirzepatide is a powerful tool within an approach that includes:

• Medical and analytical evaluation
• Nutritional guidance: not extreme restrictive diets, but adaptations to changes in appetite and protein needs
• Physical activity plan: preserve and increase muscle mass during weight loss
• Body composition monitoring: so that loss is fat, not muscle
• Complementary devices when necessary

The drug accelerates the process. Habits consolidate it. Medical monitoring makes it safe.

Frequently Asked Questions

Can I start Mounjaro without a prior medical consultation?

Not at Santé. Mounjaro is a prescription medication that requires a medical evaluation before being prescribed. This is not a formality — it is the guarantee that you are taking the correct drug at the correct dose with appropriate monitoring.

How long do I need to be on treatment?

It depends on the goal. For significant weight loss, studies show results in 52-72 weeks. The actual duration of treatment is discussed with the doctor based on individual goals and response.

Will I regain weight after stopping it?

Weight rebound is a reality in pharmacological weight treatments when discontinued without having consolidated habit changes. That's why at Santé, we work on the habit component in parallel with the pharmacological one.

Can I have other aesthetic treatments while taking Mounjaro?

Generally, yes, although each case must be evaluated. The doctor reviews the compatibility of any additional treatment with the tirzepatide protocol.

How much does the monthly treatment cost?

The cost depends on the dose and the monitoring protocol. The initial consultation (€50) includes the evaluation and prescription if indicated. The medication is obtained at a pharmacy with a medical prescription. Monthly follow-ups have their own cost, which the doctor details during the first visit.